相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Prevalence and Management of Obesity in US Adults With Type 1 Diabetes
Michael Fang et al.
ANNALS OF INTERNAL MEDICINE (2023)
Real-world Evidence of Efficacy and Safety of SGLT2 Inhibitors as Adjunctive Therapy in Adults With Type 1 Diabetes: A European Two-Center Experience
Ana Palanca et al.
DIABETES CARE (2022)
Real-world data of 12-month adjunct sodium-glucose co-transporter-2 inhibitor treatment in type 1 diabetes from the German/Austrian DPV registry: Improved HbA1c without diabetic ketoacidosis
Jochen Seufert et al.
DIABETES OBESITY & METABOLISM (2022)
Glucagon-like peptide-1 receptor agonists as adjunctive treatment for type 1 diabetes: Renewed opportunities through tailored approaches?
Alessandra Kobayati et al.
DIABETES OBESITY & METABOLISM (2022)
Type 1 diabetes drug was withdrawn because of a commercial conflict of interest, charity argues
Elisabeth Mahase
BMJ-BRITISH MEDICAL JOURNAL (2022)
Efficacy of GLP-1 RA Approved for Weight Management in Patients With or Without Diabetes: A Narrative Review
Mojca Jensterle et al.
ADVANCES IN THERAPY (2022)
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension
John P. H. Wilding et al.
DIABETES OBESITY & METABOLISM (2022)
Clinical and Safety Outcomes With GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 1 Diabetes: A Real-World Study
Khary Edwards et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2022)
Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study br
Gabriel A. Gregory et al.
LANCET DIABETES & ENDOCRINOLOGY (2022)
The Management of Type 1 Diabetes in Adults. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Richard I. G. Holt et al.
DIABETES CARE (2021)
Cardiovascular Disease in Type 1 Diabetes Mellitus: Epidemiology and Management of Cardiovascular Risk
Cristina Colom et al.
JOURNAL OF CLINICAL MEDICINE (2021)
SGLT2i versus ARNI in heart failure with reduced ejection fraction: a systematic review and meta-analysis
Yuling Yan et al.
ESC HEART FAILURE (2021)
SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
Emily Brown et al.
LANCET (2021)
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
Stefan D. Anker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
The Role of SGLT2 Inhibitors in Heart Failure: A Systematic Review and Meta-Analysis
Vasiliki Tsampasian et al.
CARDIOLOGY RESEARCH AND PRACTICE (2021)
Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulin-pump-treated patients with type 1 diabetes: The Lira Pump trial-a randomized, double-blinded, placebo-controlled trial
Thomas F. Dejgaard et al.
DIABETES OBESITY & METABOLISM (2020)
Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial
Nicklas J. Johansen et al.
LANCET DIABETES & ENDOCRINOLOGY (2020)
Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes
Marc Evans et al.
DIABETES THERAPY (2020)
Dapagliflozin in Patients with Chronic Kidney Disease
Hiddo J. L. Heerspink et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Incretin Hormones and Type 2 Diabetes-Mechanistic Insights and Therapeutic Approaches
Geke Aline Boer et al.
BIOLOGY-BASEL (2020)
International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors
Thomas Danne et al.
DIABETES CARE (2019)
SGLT2 Inhibitors Increase the Risk of Diabetic Ketoacidosis Developing in the Community and During Hospital Admission
Peter S. Hamblin et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
Pharmacologic treatment options for type 1 diabetes: what's new?
Laura M. Nally et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2019)
SGLT Inhibitors for Type 1 Diabetes: Proceed With Extreme Caution
Joseph I. Wolfsdorf et al.
DIABETES CARE (2019)
SGLT2 inhibitor or GLP-1 receptor agonist in type 2 diabetes?
Andre J. Scheen
LANCET DIABETES & ENDOCRINOLOGY (2019)
NICE guidance on dapagliflozin with insulin for type 1 diabetes
Amanda I. Adler et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016-2018
Nicole C. Foster et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2019)
SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks
Simeon I. Taylor et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Cardiovascular and Renal Benefits of SGLT2 Inhibitors: A Narrative Review
Soghra Rabizadeh et al.
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM (2019)
Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study
John B. Buse et al.
DIABETES CARE (2018)
HbA(1c) and Hypoglycemia Reductions at 24 and 52 Weeks With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: The European inTandem2 Study
Thomas Danne et al.
DIABETES CARE (2018)
Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial
Chantal Mathieu et al.
DIABETES CARE (2018)
Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study
Paresh Dandona et al.
DIABETES CARE (2018)
Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials
Julio Rosenstock et al.
DIABETES CARE (2018)
Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial
Andrew J. Ahmann et al.
DIABETES CARE (2018)
Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor
Michael Fralick et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Use of Adjuvant Pharmacotherapy in Type 1 Diabetes: International Comparison of 49,996 Individuals in the Prospective Diabetes Follow-up and T1D Exchange Registries
Sarah K. Lyons et al.
DIABETES CARE (2017)
Effect of weight reduction on glycated haemoglobin in weight loss trials in patients with type 2 diabetes
Anders Gummesson et al.
DIABETES OBESITY & METABOLISM (2017)
SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System
Gian Paolo Fadini et al.
DIABETOLOGIA (2017)
Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial
Bo Ahren et al.
DIABETES CARE (2016)
Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial
Chantal Mathieu et al.
DIABETES CARE (2016)
Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial
Thomas Fremming Dejgaard et al.
LANCET DIABETES & ENDOCRINOLOGY (2016)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme
K. Niswender et al.
DIABETES OBESITY & METABOLISM (2013)
From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
Ralph A. DeFronzo
DIABETES (2009)
分享论文
